Optimization of electroporation conditions for Mycobacterium avium

Tuberculosis

Volumn 82, Issue 4-5, 2002, Pages 167-174

  Lee, S H ^a,f   Cheung, M ^b   Irani, V ^c   Carroll, J D ^d   Inamine, J M ^e   Howe, W R ^e   Maslow, Joel N ^b,c  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^e Department of Environmental and Radiological Health Sciences   (United States)

^f HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ETHAMBUTOL; ETHIONAMIDE; GLYCINE; GREEN FLUORESCENT PROTEIN; ISONIAZID; PLASMID DNA; SUCROSE;

ARTICLE; BACTERIAL GROWTH; BACTERIUM TRANSFORMATION; CONTROLLED STUDY; CULTURE MEDIUM; DNA TRANSFER; DOT HYBRIDIZATION; ELECTROPORATION; GENE AMPLIFICATION; MYCOBACTERIUM AVIUM; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; TEMPERATURE SENSITIVITY;

MYCOBACTERIUM AVIUM;

EID: 0036452156     PISSN: 14729792     EISSN: None     Source Type: Journal    
DOI: 10.1054/tube.2002.0335     Document Type: Article

References (32)

1. Benson C A. Disease due to Mycobacterium avium complex in patients with AIDS: Epidemiology and clinical syndromes. Clin Infect Dis 1994; 18: S218-S222.
2. Havlir D, Dubé M, Sattler F et al. Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both. N Engl J Med 1996; 335: 392-398.
3. Pierce M, Crampton S, Henry D et al. A randomized trial of clarithromycin as prophylaxis against disseminated Mycobacterium avium complex infections in patients with advanced acquired immunodeficiency syndrome. N Engl J Med 1996; 335: 384-391.
4. Shafran S, Singer J, Zarowny D et al. A comparison of two regimens for the treatment of Mycobacterium avium complex bacteremia in AIDS: Rifabutin, ethambutol, and clarithromycin versus rifampin, ethambutol, clofazimine, and ciprofloxacin. N Engl J Med 1996; 335: 377-383.
5. Burman W J, Stone B L, Reitmeijer C A, Maslow J, Cohn D L, Reves R R. Long-term outcomes of treatment of Mycobacterium avium complex bacteremia using a clarithromycin-containing regimen. AIDS 1998; 12: 1309-1315.
6. Beggs M L, Crawford J T, Eisenach K D. Isolation and sequencing of the replication region of Mycobacterium avium plasmid pLR7. J Bacteriol 1995; 177: 4836-4840.
7. Howard N S, Gomez J E, Ko C, Bishai W R. Color selection with a hygromycin-resistance-based Escherichia coli-mycobacterial shuttle vector. Gene 1995; 166: 181-182.
8. Wards B J, Collins D M. Electroporation at elevated temperatures substantially improves transformation efficiency of slow-growing mycobacteria. FEMS Microbiol Lett 1996; 145: 101-105.
9. Jacobs Jr, W R, Kalpana G V, Cirillo J D et al. Genetic systems for mycobacteria. In: Miller JH, ed. Methods of Enzymology, Vol. 204. San Diego: Academic Press, Inc., 1991: pp. 537-555.
10. Arbeit R D, Slutsky A, Barber T W et al. Genetic diversity among strains of Mycobacterium avium causing monoclonal and polyclonal bacteremia in patients with AIDS. J Infect Dis 1993; 167: 1384-1390.
11. Slutsky A M, Arbeit R D, Barber T W et al. Polyclonal infection due to Mycobacterium avium complex in patients with AIDS detected by pulsed field gel electrophoresis of sequential clinical isolates. J Clin Microbiol 1994; 32: 1773-1778.
12. Maslow J N, Dawson D, Carlin E A, Holland S M. Hemolysin as a virulence factor for systemic infection with isolates of Mycobacterium avium complex. J Clin Microbiol 1999; 37: 445-446.
13. Cormack B P, Valdivia R H, Falkow S. FACS-optimized mutants of the green fluorescent protein (GFP). Gene 1996; 173: 33-38.
14. Stover C K, de la Crux V F, Fuerst T R et al. New use of BCG for recombinant vaccines. Nature 1991; 351: 456-460.
15. Livak K J, Whitehorn E A. Half-site editing: An in vitro mutagenesis procedure for truncating a DNA fragment and introducing a new restriction site. Anal Biochem 1986; 152: 66-73.
16. Lee M H, Pascopella L, Jacobs Jr, W R, Hatfull G F. Site-specific integration of mycobacteriophage LS: Integration-proficient vectors for Mycobacterium smegmatis, Mycobacterium tuberculosis, and bacille Calmette-Guerin. Proc Natl Acad Sci (USA) 1991; 88: 3111-3115.
17. Maslow J N, Mulligan M E, Adams K S, Justis J C, Arbeit R D. Bacterial adhesins and host factors in the development and outcome of Escherichia coli bacteremia. Clin Infect Dis 1993; 17: 89-97.
18. Maslow J N, Whittam T, Wilson R A et al. Clonal relationship among bloodstream isolates of Escherichia coli. Infect Immun 1995; 63: 2409-2417.
19. Gay P, Le Coq D, Steinmetz M, Berkelman T, Kado C I. Positive selection procedure for entrapment of insertion sequence elements in Gram-negative bacteria. J Bacteriol 1985; 164: 918-921.
20. Rastogi N, Labrousse V. Extracellular and intracellular activities of clarithromycin used alone and in association with ethambutol and rifampin against Mycobacterium avium complex. Antimicrob Agents Chemother 1991; 35: 462-470.
21. Rastogi N, Barrow W W. Cell envelope constituents and the multifaceted nature of Mycobacterium avium pathogenicity and drug resistance. Res Microbiol 1994; 145: 243-252.
22. Hammes W, Schleifer K H, Kandler O. Mode of action of glycine on the biosynthesis of peptidoglycan. J Bacteriol 1973; 116: 1029-1053.
23. Hermans J, Boschloo J G, de Bont J A M. Transformation of Mycobacterium aurum by electroporation: The use of glycine, lysozyme and isonicotinic acid hydrazide in enhancing transformation efficiency. FEMS Microbiol Lett 1990; 72: 221-224.
24. Winder F G, Collins P G. Inhibition by isoniazid of synthesis of mycolic acids in Mycobacterium tuberculosis. J Gen Microbiol 1970; 63: 41-48.
25. Mdluli K, Slayden R A, Zhu Y et al. Inhibition of a Mycobacterium tuberculosis beta-ketoacyl ACP synthase by isoniazid. Science 1998; 280: 1607-1610.
26. Khoo K H, Douglas E, Azadi P et al. Truncated structural variants of lipoarabinomannan in ethambutol drug-resistant strains of Mycobacterium smegmatis. Inhibition of arabinan biosynthesis by ethambutol. J Biol Chem 1996; 271: 28682-28690.
27. David H L, Rastogi N, Clavel-Seres S, Clement F. Alterations in the outer wall architecture caused by the inhibition of C-mycoside biosynthesis in Mycobacterium avium. Curr Microbiol 1988; 17: 61-68.
28. Rastogi N, Goh K-S, David H L. Enhancement of drug susceptibility of Mycobacterium avium by inhibitors of cell envelope synthesis. Antimicrob Agents Chemother 1990; 34: 759-764.
29. Steinmetz M, Le Coq D, Djjemia H B, Gay P. Genetic analysis of sacB, the structural gene of a secreted enzyme, levansucrase of Bacillus subtilis Marburg. Mol Gen Genet 1983; 191: 131-144.
30. Pelicic V, Reyrat J-M, Gicquel B. Expression of the Bacillus subtilis sacB gene confers sucrose sensitivity on mycobacteria. J Bacteriol 1996; 178: 1197-1199.
31. Pelicic V, Jackson M, Reyrat J M, Jacobs Jr, W R, Gicquel B, Guilhot C. Efficient allelic exchange and transposon mutagenesis in Mycobacterium tuberculosis. Proc Natl Acad Sci (USA) 1997; 94: 10955-10960.
32. Belisle J T, Klaczkiewicz K, Brennan P J, Jacobs W R, Inamine J M. Rough morphological variants of Mycobacterium avium. Characterization of genomic deletions resulting in the loss of glycopeptidolipid expression. J Biol Chem 1993; 268: 10517-10523.